+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multicenter comparison of inhibitor development on plasma-derived vs recombinant factor VIII in severe hemophilia A patients



Multicenter comparison of inhibitor development on plasma-derived vs recombinant factor VIII in severe hemophilia A patients



Blood 94(10 SUPPL 1 PART 1): 238a, Nov 15




(PDF emailed within 1 workday: $29.90)

Accession: 035349752

Download citation: RISBibTeXText


Related references

Rates of Inhibitor development in previously untreated patients with severe hemophilia A treated with plasma-derived or recombinant factor VIII: no proof of difference or proof of no difference?. Seminars in Thrombosis and Hemostasis 40(2): 269-270, 2014

Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. Journal of Medical Economics 21(8): 762-769, 2018

Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Critical Reviews in Oncology/Hematology 81(1): 82-93, 2012

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. Journal of Thrombosis and Haemostasis 8(6): 1256-1265, 2010

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 109(11): 4693-4697, 2007

Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thrombosis and Haemostasis 71(5): 544-547, 1994

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood 124(23): 3398-3408, 2015

Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A. Haematologica 103(1): 179-189, 2017

Incidence of Factor VII Inhibitor Development in Severe Hemophilia A Patients Treated only with One Brand of Highly Purified Plasma-Derived Concentrate. Thrombosis & Haemostasis 73(2): 215-218, 1995

Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review. Journal of Thrombosis and Haemostasis 16(6): 1055-1068, 2018

Safety and efficacy of ReFacto, the B domain-deleted recombinant factor VIII , in home therapy of previously treated patients with severe hemophilia A An Italian multicenter trial. Blood 96(11 Part 1): 262a, November 16, 2000

French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance. Thrombosis and Haemostasis 80(5): 779-783, 1998

Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfusion Science 19(2): 139-148, 1998

Pharmacokinetics of recombinant and plasma-derived factor IX products in pediatric patients with severe hemophilia B. Blood Coagulation and Fibrinolysis 26(1): 113-114, 2015

The use of recombinant factor VIII products in previously treated patients with hemophilia A: pharmacokinetics, efficacy, safety, and inhibitor development. Seminars in Thrombosis and Hemostasis 28(3): 241-246, 2002